All Oncology News

Patients with HER2-positive breast cancer that was ≤2 cm experienced a substantial improvement in disease-free and overall survival when treated with adjuvant trastuzumab.

Findings from a second phase II clinical trial have demonstrated impressive signs of clinical activity with the anti-CD38 monoclonal antibody daratumumab as a monotherapy for patients with heavily pretreated multiple myelom.

Radium-223 dichloride (Xofigo) has shown a significant survival advantage in treating patients with metastatic castration-resistant prostate cancer who have symptomatic bone metastases.

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.

The FDA has accepted an application for afatinib (Gilotrif) as a treatment for patients with squamous cell non–small cell lung cancer following progression on chemotherapy.

Susan M. O'Brien, MD, discusses the impact and the future outlook for idelalisib and ibrutinib in chronic lymphocytic leukemia.

Patients who have HPV 16 DNA in their saliva following treatment of their oropharyngeal cancer are more likely to have their cancer recur, and a prospective cohort study has shown that a simple mouth rinse can be used to detect it.

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for $410 million, with additional milestone and royalty payments of up to $160 million.

Patients with follicular lymphoma progressing within 2 years on first-line R-CHOP have a 5-year overall survival rate of only 50%, compared with 90% in longer responders.

Cabozantinib (Cometriq) has received a breakthrough therapy designation from the FDA for the treatment of patients with advanced renal cell carcinoma following one prior therapy.

The FDA has approved eltrombopag as a treatment for pediatric patients with chronic immune thrombocytopenic purpura following a lack of response to other therapies or splenectomy.

The anti-CD20 agent obinutuzumab improved overall response and had acceptable toxicity compared with rituximab in patients with relapsed indolent non-Hodgkin Lymphoma, according to the final results from the GAUSS study.

Grzegorz S. Nowakowski, MD, responds to questions raised regarding the use of immunohistochemistry in his phase II study, as well as future plans for the investigation of R2-CHOP in non-GCB DLBCL.

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

The European Medicines Agency has accepted a marketing authorization application for ixazomib in combination with lenalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma.

The European Commission has approved the hedgehog inhibitor sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy.

Fox Chase Cancer Center's breast cancer program has earned full accreditation for the third time from The National Accreditation Program for Breast Centers.

Alliance will share news about research and supportive care services.

The attenuated vaccinia virus GL-ONC1 demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy for patients with locoregionally advanced head and neck carcinoma in a recent phase I study.

The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma.

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

The FDA has approved the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin lymphoma who are at risk of relapse or progression.

Atezolizumab met the primary endpoint of objective response in PD-L1–positive patients with advanced non–small cell lung cancer in the phase II BIRCH trial.

Patients with HER2-positive breast cancer who harbor a PIK3CA mutation are less likely to benefit from the combination of trastuzumab plus lapatinib.

Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals.

Owen A. O'Connor, MD, PhD, discusses the evolving use of the anti-CD30 agent brentuximab vedotin across several lymphoma types.

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.

Treatment with single-agent venetoclax has met the primary endpoint of a pivotal phase II study for patients with relapsed or refractory chronic lymphocytic leukemia harboring the 17p deletion.

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

117-year-old facility is only comprehensive cancer center in Upstate New York